<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368749">
  <stage>Registered</stage>
  <submitdate>12/06/2015</submitdate>
  <approvaldate>6/07/2015</approvaldate>
  <actrnumber>ACTRN12615000701527</actrnumber>
  <trial_identification>
    <studytitle>Growth Hormone testing after stroke (GROWTH)</studytitle>
    <scientifictitle>Investigating differences in Human Growth Hormone levels between stroke survivors and the general population.</scientifictitle>
    <utrn />
    <trialacronym>GROWTH</trialacronym>
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Stroke</healthcondition>
    <healthcondition>Human Growth Hormone deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>No interventions are being tested.  One-off investigation of each participant's HGH levels will be conducted by a baseline blood sample and repeated blood samples at 15 minute intervals over 75 minutes after a single injection of arginine (500mg/Kg up to a maximum dose of 30000mg) and human growth hormone releasing hormone (1microgram/Kg up to a maximum dose of 100 micrograms).</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determining the prevalence of human growth hormone deficiency in stroke survivor, defined as a serum HGH concentration of less than 10ng/ml assessed by the arginine/HGHRH test.</outcome>
      <timepoint>One time point, within 5 years of stroke.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>None</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Ischemic stroke within 5 years.
18 years of age or older
Modified Rankin Score (mRS) of 3 or less 
Can speak reasonable English, understand instructions and 
be able to complete tests and questionnaires on their own or 
with minimal support
Able to give informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>pre-existing depression, dementia or other neuropsychiatric disease 

stroke induced by trauma, infection or surgery

current or past drug abuse

known active malignancy, any intracranial tumor, subdural 

or epidural hematoma

renal or hepatic impairment

use of benzodiazepines or antiepileptic drugs 

patients on immunosuppression or known immunodeficiency state e.g. HIV</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>Testing the rate of human growth hormone (HGH) deficiency in the stroke survivor population. Currently the population rate of HGH deficiency should be near zero.  This is a hypothesis-generating pilot study as there were no previous data from stroke patients on which to base a sample-size calculation.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>3/08/2015</anticipatedstartdate>
    <actualstartdate>15/03/2016</actualstartdate>
    <anticipatedenddate>1/07/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>John Hunter Hospital Royal Newcastle Centre - New Lambton</hospital>
    <postcode>2305 - New Lambton Heights</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>John Hunter Hospital</primarysponsorname>
    <primarysponsoraddress>Locked Bag 1, Hunter Region Mail Centre, NSW 2310</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Charitable donation to the Hunter Medical Research Institute</fundingname>
      <fundingaddress>Hunter Medical Research Institute
1 Kookaburra Circuit, New Lambton Heights NSW 2305</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Ischaemic stroke may affect a number of hormone pathways involving the pituitary gland in the brain, including the production of human growth hormone (HGH).  Disruption of HGH production may contribute to a number of the long-term clinical symptoms experienced by stroke survivors.  This study aims to investigate whether HGH deficiency is common in stroke survivors.  This is a hypothesis-generating pilot study which may lead to bigger studies in the future.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Local Health District Research Ethics</ethicname>
      <ethicaddress>Research Ethics and Governance Unit
Hunter New England Local Health District 
Locked Bag 1
New Lambton NSW 2305 </ethicaddress>
      <ethicapprovaldate>15/07/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>17/06/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Christopher Levi</name>
      <address>Hunter Medical Research Institute
1 Kookaburra Circuit, New Lambton Heights NSW 2305</address>
      <phone>612 40421606</phone>
      <fax />
      <email>christopher.levi@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Bivard</name>
      <address>Hunter Medical Research Institute
1 Kookaburra Circuit, New Lambton Heights NSW 2305</address>
      <phone>612 40421606</phone>
      <fax />
      <email>andrew.bivard@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Bivard</name>
      <address>Hunter Medical Research Institute
1 Kookaburra Circuit, New Lambton Heights NSW 2305</address>
      <phone>612 40421606</phone>
      <fax />
      <email>andrew.bivard@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Andrew Bivard</name>
      <address>HMRI
Kookaburra cct</address>
      <phone>612 40421606</phone>
      <fax />
      <email>andrew.bivard@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>